Abstract
The uptake of TB preventive therapy (TPT) for child and adult contacts of index TB patients in Nigeria has been suboptimal. Nigeria introduced the 3-month isoniazid-rifampicin (3HR) shorter regimen TPT for all eligible contacts through the USAID-funded Stop TB Partnership introducing New Tools Project (iNTP). This study assesses the facilitators and barriers to the uptake of the newly introduced child-friendly 3HR TPT for child contacts of TB patients in Nigeria.
This was a cross-sectional descriptive study using mixed methods. In-depth interviews were conducted among 36 purposely selected Healthcare Workers (HCWs) and 36 caregivers of child contacts. Records of TPT-eligible child contacts (0–14 years) from April to September 2022 were retrospectively extracted. Study data were analyzed using appropriate statistical tools for qualitative and quantitative techniques.
There were 7,906 child contacts identified, of which 7,902 (99.9%) contacts were screened for TB, 1,704 (21.5%) were presumptive, 264 (15.5%) diagnosed with TB, and 6,994 were eligible for TB Preventive Therapy. Additionally, out of 6,994 eligible child contacts, 3984 (57%) were initiated on TPT with 2,982 (74,8%) enrolled on 3HR and 1,002 (25%) on 6H. Of the clients placed on 3HR, 2,499 (85%) completed treatment, 309 (10.5%) lost to follow-up, 27(0.92%) developed Tuberculosis while 48 (1.6%) interrupted treatment.
The key drivers of 3HR TPT uptake among child contacts were TPT-related health education and counseling. Access barriers to 3HR TPT elicited included stigma, poverty, transportation cost, stock out, ineffective monitoring and management of side effects issues of 3HR TPT, subpar Government funding and commitment to addressing TPT implementation challenges and inadequate knowledge among HCWs and caregivers.
In conclusion, 3HR-TPT uptake among child contacts of index TB patients was high. Enhanced provider training and intensive community health education should be sustained while identified individual, structural, and institutional barriers should be addressed to improve implementation.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
Funding Statement
The study was funded by the United States Agency for International Development (USAID) through the Stop TB Partnership introducing New Tools Project (iNTP).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB NAME: National Health Research Ethics Committee of Nigeria NHREC Approval Number: NHREC/01/01/2007-29/04/2023 Date: 29th of April, 2023
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
The corresponding author may provide the data supporting the findings of the research upon reasonable request but, the data are not publicly available. Dr. Sunday Olarewaju can be contacted at sunday.olarewaju@uniosun.edu.ng with requests for access to data. Justification for Selecting Data Availability Upon Request for Our Manuscript In alignment with ethical research practices and a commitment to transparency, I am making the data from this study available upon request. This decision is rooted in several key considerations: 1. Ethical Responsibility: Protecting participants’ privacy and confidentiality is paramount. By providing data upon request, I ensure that sensitive information is shared responsibly in accordance with ethical guidelines and participant consent agreements. 2. Transparency and Reproducibility: Sharing data fosters transparency and allows other researchers to validate findings, contributing to the integrity of the scientific process. However, I aim to balance this with the necessity of protecting participants’ identities and sensitive information. 3. Data Integrity: By controlling access to the data, I can ensure that it is used appropriately and responsibly, enabling me to maintain oversight on how the data is utilized in subsequent research. 4. Institutional Compliance: This approach aligns with my institution's policies regarding data sharing and participants’ confidentiality, ensuring that I adhere to established ethical standards. I believe this approach supports the advancement of knowledge while upholding the highest ethical standards in research. Thank you for considering this justification
